
Specialty Generics Market by Type (Injectables, Oral Drugs), Application (Hepatitis C, Inflammatory Conditions, Multiple Sclerosis), End-Use - Global Forecast 2024-2030
Description
Specialty Generics Market by Type (Injectables, Oral Drugs), Application (Hepatitis C, Inflammatory Conditions, Multiple Sclerosis), End-Use - Global Forecast 2024-2030
The Specialty Generics Market size was estimated at USD 84.86 billion in 2023 and expected to reach USD 93.56 billion in 2024, at a CAGR 10.73% to reach USD 173.25 billion by 2030.
Global Specialty Generics Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Specialty Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Specialty Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Specialty Generics Market, highlighting leading vendors and their innovative profiles. These include Akorn Operating Company LLC, Apotex Inc., Aspen Group, Aurobindo Pharma Limited, Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International plc, Fresenius Kabi AG, Generic Specialties, Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group.
Market Segmentation & Coverage
This research report categorizes the Specialty Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Type
Injectables
Oral Drugs
Application
Hepatitis C
Inflammatory Conditions
Multiple Sclerosis
Oncology
End-Use
Hospital Pharmacy
Retail Pharmacy
Specialty Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Specialty Generics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Specialty Generics Market?
3. What are the technology trends and regulatory frameworks in the Specialty Generics Market?
4. What is the market share of the leading vendors in the Specialty Generics Market?
5. Which modes and strategic moves are suitable for entering the Specialty Generics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
195 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Specialty Generics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing adoption of specialty generic medicines for the treatment of complex chronic diseases
- 5.1.1.2. Presence of supportive regulatory policies regarding the approval of new products
- 5.1.1.3. Significant investments for drug development
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with specialty generics
- 5.1.3. Opportunities
- 5.1.3.1. Availability of medically advanced companies and proliferating research & development programs
- 5.1.3.2. High patient population and growing demand for affordable healthcare facilities
- 5.1.4. Challenges
- 5.1.4.1. Concerns regarding development and marketing costs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Specialty Generics Market, by Type
- 6.1. Introduction
- 6.2. Injectables
- 6.3. Oral Drugs
- 7. Specialty Generics Market, by Application
- 7.1. Introduction
- 7.2. Hepatitis C
- 7.3. Inflammatory Conditions
- 7.4. Multiple Sclerosis
- 7.5. Oncology
- 8. Specialty Generics Market, by End-Use
- 8.1. Introduction
- 8.2. Hospital Pharmacy
- 8.3. Retail Pharmacy
- 8.4. Specialty Pharmacy
- 9. Americas Specialty Generics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Specialty Generics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Specialty Generics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Akorn Operating Company LLC
- 13.1.2. Apotex Inc.
- 13.1.3. Aspen Group
- 13.1.4. Aurobindo Pharma Limited
- 13.1.5. Bausch Health Companies Inc.
- 13.1.6. Cipla Limited
- 13.1.7. Dr. Reddy's Laboratories Ltd.
- 13.1.8. Endo International plc
- 13.1.9. Fresenius Kabi AG
- 13.1.10. Generic Specialties, Inc.
- 13.1.11. Hikma Pharmaceuticals PLC
- 13.1.12. Lupin Limited
- 13.1.13. Mallinckrodt Pharmaceuticals
- 13.1.14. Novartis AG
- 13.1.15. Pfizer Inc.
- 13.1.16. STADA Arzneimittel AG
- 13.1.17. Sun Pharmaceutical Industries Ltd.
- 13.1.18. Teva Pharmaceutical Industries Ltd.
- 13.1.19. Viatris Inc.
- 13.1.20. Zydus Group
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. SPECIALTY GENERICS MARKET RESEARCH PROCESS
- FIGURE 2. SPECIALTY GENERICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. SPECIALTY GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. SPECIALTY GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. SPECIALTY GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. SPECIALTY GENERICS MARKET DYNAMICS
- FIGURE 7. SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 8. SPECIALTY GENERICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. SPECIALTY GENERICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
- FIGURE 12. SPECIALTY GENERICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES SPECIALTY GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SPECIALTY GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. SPECIALTY GENERICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. SPECIALTY GENERICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.